Testing effectiveness (Phase 2)Looking for participantsNCT02992210What this trial is testingStudy on GD2 Positive Solid Tumors by 4SCAR-GD2Who this might be right forSolid Tumor Shenzhen Geno-Immune Medical Institute 100
Early research (Phase 1)Study completedNCT01662804What this trial is testingHumanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid TumorsWho this might be right forNeuroblastoma Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03373097What this trial is testingAnti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid TumorsWho this might be right forNeuroblastomaNeuroblastoma RecurrentGD2-positive Solid Tumors+3 more Bambino Gesù Hospital and Research Institute 42
Early research (Phase 1)Study completedNCT00003750What this trial is testingBiological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other TumorsWho this might be right forMelanoma (Skin)NeuroblastomaSarcoma+1 more Children's Oncology Group 28
Testing effectiveness (Phase 2)UnknownNCT02173093What this trial is testingActivated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and OsteosarcomaWho this might be right forDisseminated NeuroblastomaRecurrent Neuroblastoma University of Virginia 40
Testing effectiveness (Phase 2)Looking for participantsNCT05437315What this trial is testingGD2/PSMA Bi-specific CAR-T Cell TherapyWho this might be right forSolid Tumor Shenzhen Geno-Immune Medical Institute 60
Early research (Phase 1)Active Not RecruitingNCT03635632What this trial is testingC7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)Who this might be right forRelapsed NeuroblastomaRefractory NeuroblastomaRelapsed Osteosarcoma+4 more Baylor College of Medicine 94